Delphine Lee

Dr. Delphine Lee

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
ACAndrew W. Chung
Andrew W. Chung
Kartik AnandKartik Anand
Kartik Anand
AAAnn C. Anselme
Ann C. Anselme
ACAlfred A. Chan
Alfred A. Chan
NGNakul Gupta
Nakul Gupta
JCJenny C. Chang
Jenny C. Chang
A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.

4 March 2020 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
MKM. Kremenovic
M. Kremenovic
MSMirjam Schenk
Mirjam Schenk
DLDelphine Lee
Delphine Lee
The incidence of cutaneous melanoma and the mortality rate of advanced melanoma patients continue to rise globally. Despite the recent success of immunotherapy including ipilimumab and pembrolizumab checkpoint inhibitors, a large proportion of patients are refractory to such treatment modalities. The application of mycobacteria such as Bacillus Calmette–Guérin (BCG) in the treatment of various malignancies, including cutaneous melanoma, has been clearly demonstrated after almost a century of observations and experimentation. Intralesional BCG (IL‐BCG) immunotherapy is a highly efficient and cost‐effective treatment option for inoperable stage III in‐transit melanoma, as recommended in the National Comprehensive Cancer Network Guidelines. IL‐BCG has shown great efficacy in the regression of directly injected metastatic melanoma lesions, as well as distal noninjected nodules in immunocompetent patients. Clinical and preclinical studies have shown that BCG serves as a strong immune modulator, inducing the recruitment of various immune cells that contribute to antitumour immunity. However, the specific mechanism of BCG‐mediated tumour immunity remains poorly understood. Comparative genome analyses have revealed that different BCG strains exhibit distinct immunological activity and virulence, which might impact the therapeutic response and clinical outcome of patients. In this review, we discuss the immunostimulatory potential of different BCG substrains and highlight clinical studies utilizing BCG immunotherapy for the treatment of cutaneous melanoma. Furthermore, the review focuses on the cellular and molecular mechanisms of the BCG‐induced immune responses of both the innate and adaptive arms of the immune system. Furthermore, the review discussed the administration of BCG as a monotherapy or in combination with other immunotherapeutic or chemotherapeutic agents.

11 August 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
RLRicardo Lardone
Ricardo Lardone
ACAlfred A. Chan
Alfred A. Chan
ALAgnes F. Lee
Agnes F. Lee
LFLeland J. Foshag
Leland J. Foshag
MFMark B. Faries
Mark B. Faries
DLDelphine Lee
Delphine Lee
Intralesional (IL) Mycobacterium bovis Bacillus Calmette-Guérin (BCG) has long been a relatively inexpensive therapy for inoperable cutaneous metastatic melanoma (CMM), although IL-BCG skin mechanisms remain understudied. We analyzed IL-BCG-treated CMM lesions combined with in vitro studies to further investigate BCG-altered pathways. Since macrophages play a pivotal role against both cancer and mycobacterial infections, we hypothesized BCG regulates macrophages to promote antitumor immunity. Tumor-associated macrophages (M2) infiltrate melanomas and impair antitumor immunity. BCG-treated, in vitro-polarized M2 (M2-BCG) showed transcriptional changes involving inflammation, immune cell recruitment, cross-talk and activation pathways. Mechanistic network analysis indicated M2-BCG potential to improve IFN-γ responses. Accordingly, frequency of IFN-γ-producing CD4+ T cells responding to M2-BCG vs. mock-treated M2 increased (p<0.05). Moreover, conditioned media from M2-BCG vs. M2 elevated the frequency of granzyme B-producing CD8+ tumor-infiltrating lymphocytes (TIL) facing autologous melanoma cell lines (p<0.01). Furthermore, transcriptome analysis of IL-BCG-injected CMM relative to uninjected lesions showed immune function prevalence, with the most enriched pathways representing T cell activation mechanisms. In vitro-infected MM-derived cell lines stimulated higher frequency of IFN-γ-producing TIL from the same melanoma (p<0.05). Our data suggests BCG favors antitumor responses in CMM through direct/indirect effects on tumor microenvironment cell types including macrophages, T cells and tumor itself.

5 April 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
JYJunbao Yang
Junbao Yang
MJMaris S. Jones
Maris S. Jones
RRRomela Irene Ramos
Romela Irene Ramos
ACAlfred A. Chan
Alfred A. Chan
ALAgnes F. Lee
Agnes F. Lee
DLDelphine Lee
Delphine Lee
Mycobacterium bovis Bacille Calmette-Guerin (BCG) is listed as an intralesional therapeutic option for inoperable stage III in-transit melanoma in the National Comprehensive Cancer Network Guidelines. Although the mechanism is unknown, others have reported up to 50% regression of injected lesions and 17% regression of uninjected lesions in immunocompetent patients have been reported after direct injection of BCG into metastatic melanoma lesions in the skin. BCG and other mycobacteria express ligands capable of stimulating the g9d2 T cells. Therefore, we hypothesized that g9d2 T cells play a role in promoting BCG-mediated antitumor immunity in patients treated with intralesional BCG for in-transit cutaneous melanoma metastases. Indeed, we found g9d2 T cell infiltration in melanoma skin lesions during the course of ILBCG treatment. Gene expression analysis revealed that BCG injection elicits the expression of a vast array of chemokines in tumor lesions, including strong expression of CXCL9, 10, and 11, a set of chemokines that attract T cells expressing the CXCR3 chemokine receptor. In corroboration with our hypothesis, approximately 85% of gd T cells express high levels of CXCR3 on their surface. Importantly, the injected tumor lesions also express genes whose protein products are the antigenic ligands for gd T cells (BTN3A1 and MICB), and the cytokines that are the typical products of activated gd T cells. Interestingly, we also found that gd T cells infiltrate the regressed lesions which did not receive BCG injections. Our study suggests that g9d2 T cells may contribute to melanoma regression induced by ILBCG treatment.

8 March 2022 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
ACAndrew W. Chung
Andrew W. Chung
AKAnthony J. Kozielski
Anthony J. Kozielski
WQWei Qian
Wei Qian
JZJianying Zhou
Jianying Zhou
AAAnn C. Anselme
Ann C. Anselme
JCJenny C. Chang
Jenny C. Chang
Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into pathways that may contribute to the divergent sensitivity to chemotherapy, we compared the inflammatory profile of the two TNBC subtypes treated with docetaxel. Cellular signaling analysis determined that docetaxel activated MAPK pathway in MSL TNBCs but not BL1 TNBCs. The subsequent MAPK pathway activation in MSL TNBCs led to an IL-1A mediated cascade of autocrine inflammatory mediators including IL-6. Utilizing the humanized IL-6R antibody, tocilizumab, our in vitro and in vivo data show that MSL TNBCs treated with tocilizumab together with chemotherapy results in delayed tumor progression compared to MSL TNBCs treated with docetaxel alone. Our study highlights a molecular subset of TNBC that may be responsive to tocilizumab therapy for potential translational impact.

22 November 2023 in JID Innovations
Verified
Journal Article
Open access
ACAlfred A. Chan
Alfred A. Chan
PTPatrick T. Tran
Patrick T. Tran
DLDelphine Lee
Delphine Lee
Although prior studies have reported distinct skin microbiome profiles associated with psoriasis, differences in methods and analyses limit generalizable conclusions. Individual studies have actually reported conflicting findings; for example, Propionibacterium and Staphylococcus have been significantly associated with both psoriatic lesions and healthy skin. Qualitative reviews have attempted to summarize this body of work, but there is great variability across the studies’ findings and methods. To better unify these data, we created a meta-analysis of all publicly available datasets by utilizing a uniform bioinformatics pipeline and reference database to investigate associations of the skin microbiome in psoriasis. A total of 977 skin swab samples (341 lesional, 295 nonlesional, and 341 healthy) from 6 studies were analyzed. The aggregated analysis revealed a higher relative abundance of microorganisms, including Staphylococcus aureus and Corynebacterium simulans, among others, from patients with psoriasis than those from healthy swab samples; in addition, Cutibacterium acnes, Lawsonella unclassified, and S warneri were significantly higher in healthy samples. Furthermore, comparison of functional pathways predicted from 16S gene markers showed that L-ornithine biosynthesis and L-histidine biosynthesis were lower in psoriatic lesions than in healthy controls. Taken together, this meta-analysis allows for a more generalizable association between the skin microbiome and psoriasis.